CAPRIN-1 Antibody-Benzodiazepine Conjugate for Broader Antitumor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) using benzodiazepines for cancer treatment have limited antitumor effects and are not effective across all cancer types.
Innovation Solution
A conjugate of an antibody or a fragment thereof against the CAPRIN-1 protein linked to benzodiazepine, specifically designed with defined immunological reactivity and complementarity-determining regions, enhances antitumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ADCs using benzodiazepines are used for cancer treatment, then some antitumor effects are achieved, but the antitumor effects are limited and not effective across all cancer types
Solution Approach 1:
The patent applies local quality by designing the antibody to specifically recognize and bind to CAPRIN-1 protein, a marker highly expressed in various solid tumors. This targeted approach concentrates the therapeutic effect on cancer cells expressing CAPRIN-1 while sparing normal cells, thereby improving both the reliability of antitumor effect and adaptability across different cancer types that express this marker
2Reliability
If an antibody against CAPRIN-1 protein is used alone, then cancer specificity is achieved, but the antitumor effect is insufficient
Solution Approach 1:
The patent merges the antibody against CAPRIN-1 protein with benzodiazepine to create an antibody-drug conjugate. The antibody provides cancer specificity by targeting CAPRIN-1 on tumor cells, while the benzodiazepine component provides potent cytotoxic activity. This combination resolves the contradiction by maintaining high cancer specificity while dramatically enhancing the antitumor effect through the synergistic action of both components
Solution Approach 2:
The invention creates a composite therapeutic agent by conjugating the antibody (biological component) with benzodiazepine (chemical component). This composite structure integrates the targeting capability of the antibody with the cytotoxic power of benzodiazepine, achieving both high cancer specificity and strong antitumor effect simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate demonstrates significantly stronger antitumor effects compared to conventional ADCs, offering improved cancer treatment and prevention across various cancer types.
Implementation Method 1
the antibody or the fragment thereof has immunological reactivity with a CAPRIN-1 protein
Implementation Method 2
Some benzodiazepines are known to recognize a particular DNA sequence, bind to the DNA minor groove, block DNA synthesis, and inhibit the cell growth
Implementation Method 3
block DNA synthesis, and inhibit the cell growth, to thereby exert antitumor effects
Implementation Method 4
antibody-drug conjugates (ADCs) in which an antibody is conjugated with a drug having the strong ability to directly kill cells
Data Source
AI summary
A conjugate of an antibody or a fragment thereof linked to benzodiazepine, which bas immunological reactivity with a CAPRIN-1 protein having an amino acid sequence represented by any of even-numbered SEQ ID NOs among SEQ ID NOs: 2 to 30 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence, is useful as an antibody-drug conjugate (ADC).